Jean Georges
Alzheimer EuropeUnited States
331254 RESULTS
Alzheimer EuropeUnited States
PAPER Miller R, Ito K, Lalovic B
PAPER Romanelli MF, Morris JC, Ashkin K, Coben LA
ALZPEDIA In 2006, TAR DNA-binding protein 43 (TDP-43) was identified as the cardinal protein in the most common subtypes of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Together with the 2006 discovery of progranulin, this was a major bre
ALZPEDIA Triggering receptor expressed on myeloid cells 2 (TREM2) is a receptor of the innate immune system expressed on microglia, macrophages, dendritic cells, and osteoclasts. TREM2 is a member of the immunoglobulin superfamily. Endogenous ligands of this recep
ALZPEDIA PICALM is an accessory protein in the endocytic pathway. Ubiquitously expressed, PICALM binds to clathrin and its adaptor proteins, which together regulate the formation of the clathrin lattice during endocytosis. PICALM was identified in one of the first
ALZPEDIA The complement receptor 1 (CR1) gene encodes a transmembrane glycoprotein that functions in the innate immune system. CR1 is expressed on blood cells and microglia. As a receptor for the complement components C3b and C4b, CR1 helps regulate activation of
Decision Resources Group
ALZPEDIA Clusterin is a highly conserved glycoprotein that functions primarily as an extracellular chaperone. Multiple large genome-wide association studies (GWAS) have uncovered clusterin variants that strongly associate with late-onset Alzheimer’s disease, earni
ALZPEDIA Apolipoprotein E is a secreted apolipoprotein involved in lipid metabolism. It complexes with lipids to form lipoprotein particles that transport cholesterol and triglycerides via the bloodstream and facilitate the transfer of cholesterol and phospholipid
COMMENT The patient and carer community in Europe was disappointed by the failures of recent clinical trials in the field of Alzheimer’s disease. Alzheimer Europe therefore welcomes research into the development of simulation models for clinical trials that hopef
PAPER Rajput A, Rajput AH, Rajput ML, Encarnacion M, Bernales CQ, Ross JP, Farrer MJ, Vilariño-Güell C
PAPER Nishimoto Y, Nakagawa S, Hirose T, Okano HJ, Takao M, Shibata S, Suyama S, Kuwako K, Imai T, Murayama S, Suzuki N, Okano H
PAPER Lilo E, Wald-Altman S, Solmesky LJ, Ben Yaakov K, Gershoni-Emek N, Bulvik S, Kassis I, Karussis D, Perlson E, Weil M
RESEARCH NEWS 2013-07-11 Research News Regulatory agencies in the U.S. and Europe have endorsed a quantitative simulation tool that allows researchers to model clinical trials in mild to moderate Alzheimer’s disease. The freely available tool will allow researchers to optimize th
No filters selected